

ASX Announcement and Media Release

29 June 2004

SciGen Limited

Potential Strategic Investment in SciGen

The Directors of SciGen Limited (“SciGen” or “the Company”) announced today that the Company is in discussions with another party regarding a potential strategic investment in SciGen.

Whilst the terms of the potential investment are not yet finalised, a due diligence review is underway.

Further announcements regarding progress with this potential transaction will be made at the appropriate time.

About SciGen

SciGen Ltd is a biopharmaceutical company essentially involved in commercialising later stage research. It co-develops and markets genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen’s portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which can allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen’s competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market



SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices also in Australia, USA, Korea, Vietnam, Hong Kong and Philippines and partners in India, China, Indonesia, Israel, Poland and the Netherlands.

=====ENDS=====

Media enquiries

Mark Compton
Managing Director & CEO
Telephone: +61 2 9234 1700

Web: www.scigen.com.au